["ClTetrabenazine (["CITBZ) is a new in nivo radioligand for positron emission tomographic (PET) imaging of vesicular monoamine transporters. The in vivo distribution, metabolism and pharmacological specificity of ["C]TBZ has been determined in rodents. Regional mouse brain retention of ["C]TBZ is highest in brain regions with greatest monoaminergic innervation (striatum, hypothalamus) and can be reduced with ligands for the monoamine vesicular transporter (TBZ, ketanserin) but not haloperidol, a dopamine D, receptor antagonist. Chromatographic analysis of rat blood demonstrated rapid metabolism of ["CITBZ to radiolabeled metabolites (G(-and /?-["Cldihydrotetrabenazine) resulting from reduction of the 2-keto group. These metabolites, as well as a third potential metabolite, 9-O-desmethylTBZ, have been synthesized in unlabeled form and all three were shown to be capable of greatly reducing in vivo accumulation of ["C]TBZ in mouse striatum and hypothalamus. Whole body biodistribution of radioactivity after ["C]TBZ injection was determined in rats, and the data used to calculate the expected human dosimetry from this radiotracer. These studies demonstrated that ["C]TBZ can be safely administered for in viuo PET imaging and semi-quantitative determination of vesicular monoamine transporters in living human brain, but quantitative pharmacokinetic modeling of radioactivity distribution will be complicated by the presence of pharmacologically active metabolites.
Introduction
Vesicular monoamine transporters are located exclusively in presynaptic monoaminergic terminals, and along with the neuronal monoamine transporters (distinct for dopamine, norepinephrine and serotonin) and the enzymes involved in monoamine biosynthesis are potential targets for preparation of radioligands for in viuo imaging. Vesicular amine transporters and neuronal amine transporters are different proteins that have been recently cloned and sequenced (Giros et al., 1992; Liu et al., 1992 ) and although they both belong to the 12-transmembrane region transporter superfamily (Uhl, 1992) they are pharmacologically distinct (DaSilva and Kilbourn, 1992; Rostene et al., 1992) . Additionally, at present there is no evidence for monoamine specific subtypes of vesicular transporters.
Tetrabenazine (TBZ: Fig. 1 ) is a specific high affinity (IC,, = 3 nM) inhibitor of monoamine uptake *All correspondence should be addressed to: Dr M. R.
Kilbourn, Division of Nuclear Medicine, University of Michigan, 3480 Kresge III Bldg, Ann Arbor, MI 48109-0552, U.S.A.
into vesicles of presynaptic neurons (Scherman et al., 1988; Henry and Scherman, 1989) , which shows more selectivity in central pharmacological action and shorter duration of monoamine depletion as compared to reserpine (Pletscher et al., 1962) .
[3H]Dihydrotetrabenazine ([3H]TBZOH), a simple reduction product of TBZ, has been developed for use in in vitro assays of vesicular monoamine transporters, and for in vitro autoradiography (Scherman, 1986; Masuo et al., 1990) . Using this radioligand, Scherman and coworkers have been able to demonstrate losses of vesicular transporter binding sites in 6-hydroxydopamine lesioned rats (Masuo et al., 1990) , and in post-mortem tissue from Parkinson's disease patients .
We have recently prepared a carbon-l 1 labeled form of TBZ (DaSilva et al., 1993a) and demonstrated specific in vivo binding of ["C]TBZ in mouse brain (DaSilva and Kilbourn, 1992) . For development of this radiotracer for the in viva study vesicular amine transporters of living human brains using positron emission tomography (PET), it was also necessary to (1) further demonstrate the pharmacologic specificity of this radioligand in vivo, (2) calculate the expected human radiation dosimetry associated with its in vivo use and (3) determine the effects if any of peripheral metabolism of the radiotracer. We report here the in viuo characteristics of ["C]TBZ and its potential as a quantitative imaging agent for the study of neurodegenerative diseases.
Materials and Methods

Materials
Tetrabenazine was obtained from Fluka. Ketanserin and haldol were purchased from Sigma Chem. Co. 9-0-DesmethylTBZ (OH-TBZ) was prepared as previously described (DaSilva et al., 1993a) . a-TBZOH and fl-TBZOH were synthesized by modifications of literature methods (DaSilva et al., 1993b) . All compounds were prepared for injection in 4% ethanol:isotonic sodium phosphate buffer @H 4.5).
No-carrier-added, high specific activity (> 1000 Ci/ mmol) ['Qetrabenazine was synthesized as previously described and prepared for injection in sterile phosphate buffer (PH 6.0) (DaSilva et al., 1993a) .
Biodistribution studies
Whole-body biodistribution studies were performed in Sprague-Dawley rats (175-250 g, Charles River). Animals (5 for each data point: 3 females, 2 males) were anesthetized with diethyl ether and ["C]TBZ was injected into the femoral vein at doses of 150-635 PCi of the formulated solution (4mCi/mL). The animals were allowed to recover, then sacrificed by decapitation at 2, 15, 30 or 60 min after injection. A blood sample was collected and whole tissues were dissected out, assayed for radioactivity (automated y-counter) and weighed. Radioactivity remaining in the carcass was measured in a dose calibrator. Data were calculated as % injected dose per organ (%ID/organ).
In vivo competition studies
Pharmacological competition studies were done in female CD-l mice, 2&27 g (Charles River), in a
manner similar to that previously reported (DaSilva and Kilbourn, 1992 For all studies animals were anesthetized (diethyl ether) and i.v. injections were done via the tail vein. The mice were allowed to recover, then sacrificed by decapitation at 10min after injection. A blood sample was collected, and the brain rapidly removed and dissected into samples of striatum, cortex, hippocampus, hypothalamus, cerebellum and thalamus. All samples were assayed for radioactivity (automated gamma counter) and then weighed. These data were used to calculate the % injected dose per gram (%ID/g) for blood and for each brain region.
Metabolite studies
Metabolite studies were done in a manner analogous to that previously reported (Kilbourn et al., 1989) . ["C]TBZ (8.5 mCi in 1.0 mL) was injected via the femoral vein into a Sprague-Dawley rat (200 g). The animal was killed at 15 min and a blood sample (1 .O mL) collected with a heparinized syringe. Ethanol (0.5 mL) was added to half of the blood sample (0.5 mL) to effect hemolysis, then the mixture was vortexed briefly and centrifuged. The supernatant was drawn off and diluted with 9 mL NaHCO, (7%) (NaHCO, was used to ensure formation of the free base form of TBZ and its metabolites). The mixture was passed through a C,,Sep-Pak (Waters Co.), that was preactivated with ethanol (10 mL) and a solution of 7% NaHCO, (20 mL). The Sep-Pak was then washed with 10 mL of aqueous NaHCOr (7%), 10 mL dichloromethane and 1OmL ethanol. These fractions were then assayed for radioactivity (automated y-counter) and the organic solvents (CH,Cl,
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R=H Desmethyltetrabenazine (OH-TBZ) Fig. 1 . Structures of tetrabenazine, desmethyltetrabenazine (OH-TBZ) and dihydrotetrabenazine (TBZOH). 
Statistical anal_vsis
Statistical analysis was conducted using an unpaired Student's t-test. A P < 0.05 was considered statistically significant. 
Results
Tissue distribution
After i.v. injection of ["C]TBZ radioactivity levels were highest in the organs involved in metabolism (liver, intestines, kidney) and remained that way throughout the study period (data not shown). High levels of radioactivity were observed in the brain at an early time point f3.37 %ID/organ at 2min) and then declined rapidly (0.41 %ID/organ at 60 min). A mean of 93% of the total injected dose could be accounted for in the organs four time points studied. The were used for the calculation dosimetry.
and carcass at the biodistribution data of expected human
Calculation of human absorbed radiation dose
The expected absorbed doses to humans shown in Table 1 were calculated using the rat biodistribution data from ["C]TBZ injection, following the MIRD formalism (Loevinger and Berman, 1976) . The percent administered dose per organ values were modified to reflect the different proportions of organ to total body mass in rat and man (Roedler, 1980) . Residence times were obtained by integration under the organ time vs activity curves, with the effective half-life of ["C]TBZ assumed to be equal to the physical half-life of "C for times exceeding the last data point. Residence times were entered into the MIRDOSEZ program for the generation of absorbed doses to selected target organs per unit administered activity. 
-
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Pharmacological competition experiments
The results from drug competition studies are shown in Figs 2 and 3. Data are presented as % of control animals values determined in the same experimental set; for comparison purposes, values from the coinjection of lOmg/kg i.v. TBZ are included (DaSilva and Kilbourn, 1992) . Statistical significance was determined using the actual data for %ID/g for each brain region. Coinjection with ketanserin (2 mg/kg, iv.) significantly reduced ["CITBZ concentrations in the striatum and hypothalamus as compared to controls (Fig. 2) ; use of higher doses was limited by animal mortality. Pretreatment with 1 mg/kg haldol (i.p., 30 min prior) had no significant effect on ["C]TBZ levels of any brain region or the blood (Fig. 2) . The potential metabolites cc-TBZOH, /?-TBZOH and OH-TBZ all significantly blocked the specific binding of ["CITBZ in striatum and hypothalamus (Fig. 3) . OH-TBZ proved nearly as potent as TBZ itself, and significant reductions in radiotracer accumulation in cortex, hippocampus and cerebellum were also evident.
Metabolism experiments
The distribution of radioactivity from ["C]TBZ and labeled metabolites in rat blood at 15 min following injection of ["C]TBZ is summarized in Table 2 . The percentage of total radioactivity that partitioned into plasma upon centrifugation (after ethanol hemolysis) was 85% (15% in the pellet). TLC analyses of the organic eluants from the Sep-Pak separation of the supernatant showed unmetabolized
["CITBZ (in CH,Cl, fraction) and radioactive metabolites of ["C]TBZ with the same chromatographic mobilities (R, values) as a-TBZOH and p-TBZOH (present in both CH,Cl, and ethanol fractions). Together, these lipophilic metabolites constituted 88% of the supernatant radioactivity. Hydrophilic metabolites, including potentially any ["Clmethanol, were eluted in the NaHCO, fraction and constituted 8% of the supernatant radioactivity. Finally, a small amount (4%) of material was retained on the Sep-Pak and could not be identified.
Discussion
In uivo imaging of monoaminergic nerve terminals, and in particular dopaminergic nerve terminals, would be of great value for the study of the development and progression (and possible therapeutic treatment or prevention) of neurodegenerative diseases such as Parkinson's disease. The quantitative imaging of vesicular transporters for monoamines, a specific Quantitative PET imaging places certain important restrictions on radioligand design and development. First, adequate radiotracer must reach the tissue or region of interest to allow imaging with statistics adequate for pharmacokinetic modeling; unfortunately, for radiotracers destined for brain imaging, most of the radioactive dose does not reach the brain and the absorbed radiation dose to peripheral organs may limit allowable injectable doses for human studies. Second, within the tissue of interest, distribution of the radioactivity should be assignable to interaction with only one binding site. Finally, radioactivity within a region of interest should be attributed to one (or predominantly only one) radioactive species as external imaging cannot distinguish the chemical forms of radioactivity present in the field of view. Thus, formation of radioactive metabolites which have access to the tissue under study can severely complicate quantitative pharmacokinetic modeling of the distribution of the injected radiotracer.
As shown in Table 1 , ["C]TBZ meets the first of these requirements. The radioligand showed good rat brain uptake (2.37% injected dose/organ at 2 min) and clearance kinetics similar to those reported previously in mice (DaSilva and Kilbourn, 1992) . The low lung uptake (1.11 %ID/organ at 2 min) is appropriate for a radiotracer with relatively moderate lipophilicity [TBZ, log octanol/buffer partition coefficient (log P) = 2.681 (Scherman et al., 1988) . Radiation dosimetry is acceptable: the limiting organ for administration of the radiotracer for research purposes would be the testes (3 rad maximum), with an allowable dose of 29 mCi.
The pharmacological specificity of ["CITBZ distribution in vivo is also quite acceptable, as shown in Figs 2 and 3. Radiotracer accumulation can be reduced by treatments with drugs known to act at the vesicular transporter, such as reserpine, tetrabenazine and ketanserin. Ketanserin shows a smaller effect (Fig. 2) , perhaps due to the lower affinity of this drug for the vesicular transporter binding site (Darchen et al., 1988) or insufficient concentrations of the drug in the brain after a 2 mg/kg dose; we were prevented from administering higher doses by the toxicity of the drug. Since its initial discovery, TBZ has been considered to have excellent pharmacological specificity both in vitro and in vivo, with only binding to dopamine D, receptors reported as a possible secondary binding site (Reches et al., 1983; Login et al., 1982) . Most recently, the in vivo binding of the high affinity D, receptor antagonist ["Clraclopride was shown to be reduced by administration of a pharmacological dose of TBZ (Dewey et al., 1993) . In mouse brain we have found that uptake and retention of radioactivity from ["C]TBZ is unaffected by haloperidol, a dopamine D, receptor antagonist (Fig. 2) . The data obtained here, in combination with the lack of ["CITBZ accumulation in the striatum of a MPTP-lesioned monkey (DaSilva et al., 1993a) , provides evidence that at a tracer level ["CJTBZ predominantly binds to the presynaptic vesicular transporter site. At higher concentrations, such as those obtained from a pharmacological dose, binding to other receptors cannot be ruled out; fortunately, this is not a consideration for in vivo imaging of trace doses of radioactive drug.
The metabolism of TBZ has been previously studied in some detail. 9-O-DesmethylTBZ and TBZOH (both a-and B-isomers) have been identified as plasma metabolites formed in vivo in both animals and man (Schwartz et al., 1966; Mehvar et al., 1986 , and TBZOH has been demonstrated to be present in rat brain following administration of TBZ. From our analysis of rat blood after injection of ["CITBZ (Table 2) , ["CITBZOH is clearly formed from metabolism of this radioligand. The reduction products, cc-TBZOH and p-TBZOH, have been shown in vitro to have high affinity for the vesicular monoamine transporter (3 and 20 nM, respectively) (Scherman et al., 19881 , and TBZOH shows pharmacokinetics and monoamine-depleting actions similar to that of the parent drug TBZ (Mehvar and Jamali, 1987) . This has led to proposals that TBZOH is actually the pharmacologically important species in man following administration of TBZ. As shown in Fig. 3 , all three metabolites of TBZ (OH-TBZ, X-and /?-TBZOH) are capable of crossing the blood-brain barrier and blocking selective retention of ["CITBZ in striatum and hypothalamus of mouse brain, with nearly equal efficacy as TBZ. Our data are consistent with the reported pharmacological actions of TBZOH, and confirm that the monoamine-depleting action of that metabolite is due to its affinity for the vesicular transporter.
These data also suggest strongly that the distribution of radioactivity after peripheral administration of ["CITBZ more properly reflects both ["CITBZ and labeled metabolites, c(-and p-["CITBZOH. As we have labeled ["CITBZ in the 9-methoxy group, any OH-TBZ formed by metabolic ether cleavage at that position (Schwartz et al., 1966) would not be radiolabeled, and thus will not contribute to brain radioactivity content.
In studies using monkeys and humans, we have demonstrated that ["CITBZ can be successfully used to image vesicular amine transporters in the basal ganglia (DaSilva et al., 1993b; Kilbourn et al., 1993) . The studies of ["CITBZ reported here suggest that this radioligand will not be optimal for quantitative pharmacokinetic modeling due to the probable formation of the labeled metabolites a-and fl-["CJTBZOH, which quite likely enter the brain and contribute to the radioactivity distribution. However, as these metabolites are themselves high affinity ligands for the same binding site with similar pharmacokinetics in vim, this radioligand is very suitable for semi-quantitative imaging of vesicular amine trans-porters and in particular the dopaminergic nerve terminals of the human basal ganglia. Tetrabenazine, rather than a derivative, was chosen as the initial target for radioligand development due to the wealth of data on its pharmacology and toxicology; this allowed for rapid approval of the radiolabeled drug for human studies, and thus the potential human applications of this class of radiotracers could be evaluated. We are now concentrating our efforts on the synthesis and characterization of TBZ derivatives which will not suffer from the formation of radiolabeled metabolites which can enter the brain.
